425: Kintara Therapeutics Urges Stockholders to Vote on Proposed Merger with TuHURA Biosciences

Kintara Therapeutics is urging its stockholders to vote in favor of the proposed merger with TuHURA Biosciences at the upcoming Special Meeting.

Summary

• Kintara Therapeutics is encouraging stockholders to vote for the proposed merger with TuHURA Biosciences at the Special Meeting.
• The Special Meeting will be held virtually on September 20, 2024.
• Stockholders must vote by September 19, 2024, at 11:59 p.m. Eastern Time.
• If the merger is approved, pre-merger Kintara equity holders are expected to own up to approximately 2.85% (or approximately 5.45% including CVR shares) of the combined company.
• Pre-merger TuHURA equity holders are expected to own approximately 97.15% (or 94.55% after giving effect to the issuance of the CVR shares) of the combined company.
• The combined company is expected to operate under the name TuHURA Biosciences, Inc. and trade on the Nasdaq Capital Market under the ticker HURA.
• The transaction is subject to customary closing conditions, including stockholder approval of both companies, and is expected to close in the third quarter of 2024.
• The board of directors recommends shareholders support the merger because merging with TuHURA represents the best path forward for our shareholders and has the potential to deliver near and long-term value.
• If the proposed merger does not close, Kintara may not have sufficient capital to continue to operate the business and, without additional funding or a strategic transaction, may be required to seek the protection of the bankruptcy courts.

Sentiment

Score: 5

Explanation: The document focuses on urging stockholders to vote for the merger, highlighting potential benefits but also acknowledging the risk of Kintara's financial instability if the merger fails. The sentiment is neutral, leaning slightly negative due to the emphasis on the need for the merger to avoid potential bankruptcy.

Positives

• The merger with TuHURA is expected to create a publicly traded company with a promising therapeutic pipeline, a strong leadership team, and substantial capital resources.
• The combined company is expected to be well-positioned to develop powerful new therapies with the potential to overcome resistance to current immunotherapies.
• The board of directors believes the proposed merger represents the best path forward for Kintara stockholders and has the potential to deliver significant long-term value for stockholders.

Negatives

• Kintara stockholders will have a significantly reduced ownership stake in the combined company, owning only approximately 2.85% (or approximately 5.45% including CVR shares).
• If the proposed merger does not close, Kintara may not have sufficient capital to continue to operate the business and, without additional funding or a strategic transaction, may be required to seek the protection of the bankruptcy courts.

Risks

• The merger is subject to stockholder approval and customary closing conditions, and there is a risk that these conditions may not be met.
• There are uncertainties regarding the timing of the consummation of the merger.
• The combined company may face challenges in correctly estimating operating expenses and expenses associated with the merger.
• The announcement or pendency of the merger could negatively affect Kintara's or TuHURA's business relationships, operating results, and business generally.
• The combined business of TuHURA and Kintara may not be successful.
• There is a risk that Kineta and TuHURA do not enter into a definitive agreement for a strategic transaction.

Future Outlook

The combined company is expected to operate under the name TuHURA Biosciences, Inc. and to trade on The Nasdaq Capital Market under the ticker HURA, focusing on advancing a risk-diversified late-stage oncology pipeline.

Management Comments

• The Board of Directors believes the proposed merger will result in a publicly traded company with a promising therapeutic pipeline, a strong leadership team and substantial capital resources that will position the combined company to become a great oncology-focused company.
• The Board of Directors recommends shareholders support the merger because merging with TuHURA represents the best path forward for our shareholders and has the potential to deliver near and long-term value.
• We believe that the combined company will be well-positioned to develop powerful new therapies with the potential to overcome resistance to current immunotherapies, an area of significant unmet need.

Industry Context

The merger aims to create a stronger entity in the competitive oncology space, combining Kintara's assets with TuHURA's expertise in immuno-oncology to develop novel cancer therapies.

Comparison to Industry Standards

• TuHURA's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors, similar to approaches being developed by companies like BioNTech and Moderna in the personalized cancer vaccine space.
• TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma, which is similar to trials conducted by other companies evaluating combination therapies with checkpoint inhibitors.
• TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-functional ADCs, targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies, which is similar to approaches being developed by companies like Bristol Myers Squibb and AstraZeneca in the ADC space.

Stakeholder Impact

• Shareholders are urged to vote on the merger, which will significantly impact their ownership stake.
• Employees of both Kintara and TuHURA may be affected by the merger, with potential changes in roles and responsibilities.
• The merger could impact patients if the combined company is successful in developing new cancer therapies.

Next Steps

• Stockholders need to vote on the proposed merger by September 19, 2024.
• The Special Meeting of Stockholders will be held on September 20, 2024.
• The merger is expected to close in the third quarter of 2024, subject to stockholder approval and customary closing conditions.

Key Dates